Phase 1 N=53 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Glioma
Primary: Number of Patients Who Experienced Dose Limiting Toxicities (DLTs) — 0; 2; 0; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=13 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Phase 2 N=18 Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Anaplastic Astrocytoma · Brain Stem Glioma · Childhood Mixed Glioma
Primary: Maximum-tolerated Dose of Veliparib Defined as Highest Dose Level With Fewer Than 2 Dose Limiting Toxicities in 6 Patients as Assessed by the National Cancer Institute…
Phase 2 N=79 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Diffuse Intrinsic Pontine Glioma
Primary: Maximum Tolerated Dose (MTD) of Vorinostat — 230 mg/m^2
Phase 2 N=32 A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Phase 1 N=46 Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Diffuse Intrinsic Pontine Glioma
Primary: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose of Adavosertib — 200 mg/m^2
Phase 2 N=7 MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
Diffuse Intrinsic Pontine Glioma
Primary: Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events — 0.142; 0.142; 0.142; 0.142 proportion of participants
Phase 2 N=47 External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
Brain Cancer
Primary: Number of Participants With High-grade Astrocytoma and Diffuse Pontine Tumors Achieving One Year Progression Free Survival. — 5; 6 Participants
Phase 2 N=53 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Phase 2 N=38 Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Glial Cell Tumors · Malignant Gliomas · Glioblastoma Multiforme
Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05
Phase 2 N=50 H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
Diffuse Intrinsic Pontine Glioma · Glioma · Diffuse Midline Glioma, H3 K27M-Mutant
Primary: Percentage of Participants With Adverse Events (AE) Related to Treatment — 5.26; 0; 0; 21.0 percentage of participants
Phase 2 N=64 Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
Untreated Childhood Brain Stem Glioma
Primary: One Year Event-free Survival (EFS) — 20 percent probability
Phase 1 N=8 Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Phase 2 N=51 Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in the Phase I Component With Dose-limiting Toxicities (DLTs) Observed During the First 8 Weeks (Courses 1 and 2) of Tipifarnib Therapy — 0; 1; 4…
Phase 2 N=69 Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Untreated Childhood Anaplastic Astrocytoma · Untreated Childhood Anaplastic Oligodendroglioma · Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in Phase I Stratum 1A With Dose-limiting Toxicities (DLT) Observed During the First 8 Weeks of Gefitinib Therapy — 2; 0; 1 Participants
N/A N=66 Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
Brain Tumor · Central Nervous System Tumor
Primary: Short Term Feasibility Success — 25 participants
Phase 2 N=41 O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
Brain and Central Nervous System Tumors
Primary: Percentage of Participants With an Objective Response (Complete Response or Partial Response) — 4; 0 Percent of Participants
Phase 2 N=23 A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Phase 2 N=118 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Phase 2 N=92 Radiation Therapy in Treating Young Patients With Gliomas
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Phase 2 N=12 Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
Low-grade Glioma
Primary: Progression-free Survival — 23.1 percentage
Phase 2 N=9 Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Juvenile Pilocytic Astrocytomas · Optic Pathway Gliomas
Primary: Number of Children Responding to Treatment — 0; 0; 5 Participants
Phase 2 N=20 The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
Glioma
Primary: Proportion of Participants With Progression-free Survival — 0.85 Proportion of participants
Phase 2 N=43 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
Glioblastoma · Malignant Glioma
Primary: Overall Survival (OS) — 0.54 proportion of successes
Phase 2 N=75 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Neurofibromatosis Type 1 · Recurrent Childhood Pilocytic Astrocytoma · Recurrent Childhood Visual Pathway Glioma
Primary: Number of Patients Who Demonstrate Complete or Partial Response — 4; 4 Participants
Phase 2 N=97 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Childhood Cerebral Anaplastic Astrocytoma · Childhood Oligodendroglioma · Childhood Spinal Cord Neoplasm
Primary: Objective Response Rate Sustained for ≥ 8 Weeks — 0; 0; 0; 0 participants
Phase 2 N=83 Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
Glioma · Medulloblastoma
Primary: Percentage of Participants With Objective Response of Complete Response or Partial Response — 32.6; 0 percentage of participants
Phase 2 N=36 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Median Time to Disease Progression — 13.2 Months
Phase 2 N=151 Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Diffuse Astrocytoma · Anaplastic Astrocytoma · Astrocytoma
Primary: LGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using Response Assessment in Neuro-Oncology (RANO) Criteria — 46.6; 10.8 Percentage of…
Phase 2 N=33 Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Arm 1: Progression Free Survival (PFS) — 0; 0 Participants